
Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced results of a pre-clinical study demonstrating Ampion inhibits an important pro-inflammatory pathway in the types of immune cells... Read More
Friday April 9, 2021 0 comments